Patents by Inventor Adel Rafai Far

Adel Rafai Far has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High purity oritavancin and method of producing same
    Patent number: 10864249
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: December 15, 2020
    Assignees: MELINTA THERAPEUTICS, INC., ABBVIE INC.
    Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
  • HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME
    Publication number: 20190290723
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 26, 2019
    Applicants: Melinta Therapeutics Inc., AbbVie Inc.
    Inventors: Adel RAFAI FAR, Gopal KRISHNA, Min DING, Sanjay R. CHEMBURKAR, Carl M. KNABLE, James P. PETZEL, Julie J. PRUYNE, Douglas M. REAMER
  • High purity oritavancin and method of producing same
    Patent number: 10328118
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: June 25, 2019
    Assignees: MELINTA THERAPEUTICS, INC., ABBVIE INC.
    Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
  • Methods of inhibiting and treating biofilms using glycopeptide antibiotics
    Patent number: 10201587
    Abstract: The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: February 12, 2019
    Assignee: MELINTA THERAPEUTICS, INC.
    Inventors: Eve Neesham-Grenon, Gregory Moeck, Adam Belley, Thomas R. Parr, Jr., Adel Rafai Far
  • Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
    Patent number: 10039780
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: August 7, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
  • PHARMACEUTICAL FORMULATIONS COMPRISING HIGH PURITY CANGRELOR AND METHODS FOR PREPARING AND USING THE SAME
    Publication number: 20170304345
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Panna DUTTA, Adel RAFAI FAR, Min DING, Rajeshwar MOTHERAM
  • ORITAVANCIN FORMULATIONS
    Publication number: 20170239323
    Abstract: Disclosed herein are antibacterial compositions, pharmaceutical compositions, and the use and preparation thereof. Some embodiments relate to compositions including oritavancin and their use as therapeutic agents.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 24, 2017
    Inventors: David C. Griffith, Adel Rafai Far, Dario Lehoux, Gopal Krishna
  • Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
    Patent number: 9700575
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: July 11, 2017
    Assignee: Chiesi Farmaceutici, S.P.A.
    Inventors: Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
  • HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME
    Publication number: 20170157206
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 8, 2017
    Applicants: The Medicines Company, AbbVie Inc.
    Inventors: Adel RAFAI FAR, Gopal KRISHNA, Min DING, Sanjay R. CHEMBURKAR, Carl M. KNABLE, James P. PETZEL, Julie J. PRUYNE, Douglas M. REAMER
  • High purity oritavancin and method of producing same
    Patent number: 9649352
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: May 16, 2017
    Assignees: THE MEDICINES COMPANY, ABBVIE INC.
    Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
  • PHARMACEUTICAL FORMULATIONS COMPRISING HIGH PURITY CANGRELOR AND METHODS FOR PREPARING AND USING THE SAME
    Publication number: 20160296549
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Applicant: The Medicines Company
    Inventors: Panna DUTTA, Adel RAFAI FAR, Min DING, Rajeshwar MOTHERAM
  • Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
    Patent number: 9439921
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: September 13, 2016
    Assignee: THE MEDICINES COMPANY
    Inventors: Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
  • PHARMACEUTICAL FORMULATIONS COMPRISING HIGH PURITY CANGRELOR AND METHODS FOR PREPARING AND USING THE SAME
    Publication number: 20160199400
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Application
    Filed: February 22, 2016
    Publication date: July 14, 2016
    Applicant: The Medicine Company
    Inventors: Panna DUTTA, Adel RAFAI FAR, Min DING, Rajeshwar MOTHERAM
  • Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
    Patent number: 9295687
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: March 29, 2016
    Assignee: THE MEDICINES COMPANY
    Inventors: Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
  • HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME
    Publication number: 20160015772
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Application
    Filed: July 16, 2015
    Publication date: January 21, 2016
    Applicant: The Medicines Company
    Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James J. Petzel, Julie J. Pruyne, Douglas M. Reamer
  • Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
    Patent number: 8946144
    Abstract: The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: February 3, 2015
    Assignee: The Medicines Company
    Inventors: Kelly Tanaka, Stephane Ciblat, Adel Rafai Far, Evelyne Dietrich
  • Glycopeptide and lipoglycopeptide antibiotics with improved solubility
    Patent number: 8901072
    Abstract: The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent glycopeptide or lipoglycopeptide antibiotic under physiological conditions. These compounds are useful as antibiotics for the prevention and/or the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: December 2, 2014
    Assignee: The Medicines Company
    Inventors: Adel Rafai Far, Kelly Tanaka, Evelyne Dietrich, Ranga Reddy, Ting Kang
  • Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
    Patent number: 8524691
    Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: September 3, 2013
    Assignee: The Medicines Company
    Inventors: Evelyne Dietrich, Ranga Reddy, Kelly Tanaka, Ting Kang, Yanick LaFontaine, Adel Rafai Far
  • Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa
    Patent number: 8497245
    Abstract: The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(?O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 30, 2013
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Peter Herold, Stjepan Jelakovic, Mohammed Daghish, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz, Friedrich-Alexander Ludwig, Adel Rafai Far, Ting Kang
  • Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections
    Patent number: 8404664
    Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: March 26, 2013
    Assignee: Targanta Therapeutics, Inc.
    Inventors: Yannick Stephane Rose, Stephane Ciblat, Ting Kang, Adel Rafai Far, Evelyne Dietrich, Yanick Lafontaine, Ranga Reddy